Document:

First Amendment and Joinder to Second Amended and Restated Stockholders' Agmt

 EXHIBIT 4.6 
 FIRST AMENDMENT AND JOINDER TO 
 SECOND AMENDED AND RESTATED STOCKHOLDERS’ AGREEMENT 

(Series R Preferred Stock) 
 THIS FIRST
AMENDMENT AND JOINDER TO SECOND AMENDED AND RESTATED STOCKHOLDERS’ AGREEMENT (the “Joinder and Amendment Agreement”) is entered into as of October 26, 2004 by and among Pharmasset, Inc. a Delaware corporation (the
“Company”), Hoffmann-La Roche Inc., a New Jersey corporation (“Roche”), and the persons named under the headings “Existing Investors” (the “Existing Investors”) and “Existing
Stockholders” (the “Existing Stockholders”) on the signature pages hereto. 
 RECITALS 
 WHEREAS, pursuant to certain stock purchase and other agreements (as amended and restated, collectively, the “Prior Purchase
Agreements”), certain of the Company’s stockholders previously purchased or acquired securities of the Company and/or its predecessor and now hold (a) shares of the Company’s Series A Preferred Stock, $0.001 par value per
share (the “Series A Stock”), (b) shares of the Company’s Series B Preferred Stock, $0.001 par value per share (the “Series B Stock”), (c) shares of the Company’s Series C
Preferred Stock, $0.001 par value per share (the “Series C Stock”), (d) shares of the Company’s Series D Preferred Stock, $0.001 par value per share (the “Series D Stock”) and
(e) warrants to acquire shares of the Company’s Series D-1 Preferred Stock, $0.001 par value per share (the “Series D-1 Stock”); and 
 WHEREAS, pursuant to a Stock Purchase Agreement of even date herewith between Roche and the Company (the “Series R Purchase Agreement”), Roche has agreed to purchase and the Company has agreed to
sell an aggregate of 400,000 shares of the Company’s Series R Preferred Stock, $0.001 par value per share (the “Series R Stock”), and warrants (the “Series R-1 Warrants”) to purchase 470,588
shares of the Company’s Series R-1 Preferred Stock, $0.001 par value per share (the “Series R-1 Stock”); and 
 WHEREAS, as a condition to completing the purchase, sale and issuance of the Series R Stock and Series R-1 Warrants pursuant to the Series R Purchase Agreement, Roche has requested that the Company extend to Roche the
registration rights of an “Investor” as set forth in that certain Second Amended and Restated Stockholders’ Agreement dated as of August 4, 2004 by and among the Company, the Existing Investors and the Existing Stockholders,
a copy of which is attached as Exhibit A to this Joinder and Amendment Agreement (the “Existing Stockholders’ Agreement”) and certain other rights as specifically set forth herein; and 
 WHEREAS, the Existing Stockholders’ Agreement may only be amended with the consent of Existing Investors holding a majority of the Registrable
Securities (as defined by the Existing Stockholders’ Agreement) and the consent of Existing Stockholders (other than the Existing Investors) holding at least a majority of the Shares (as defined by the Existing Stockholders’ Agreement), on
an as-if-converted basis, held by such existing Stockholders, and an amendment to the registration rights provisions of the Existing Stockholders’ Agreement 

 
additionally requires the consent of Existing Investors holding at least two-thirds of the Registrable Securities. 
 NOW, THEREFORE, in consideration of the mutual promises, representations, warranties, covenants and conditions set forth in this Joinder and Amendment
Agreement and in the Purchase Agreement, the Existing Stockholders’ Agreement is hereby amended, and the Company, Roche, the Existing Investors and the Existing Stockholders (collectively, the “Parties”) hereby agree, as
follows: 
 SECTION 1. GENERAL 
 1.1
Definitions. Capitalized terms used but not otherwise defined in this Joinder and Amendment Agreement shall have the meanings set forth in the Existing Stockholders’ Agreement, as amended hereby. As used in the Existing Stockholders’
Agreement, as amended hereby, the term “Agreement” shall hereafter be deemed to mean the Existing Stockholders’ Agreement as amended by this Joinder and Amendment Agreement. In addition, the Existing Stockholders’ Agreement is
hereby amended so that, as used in the Existing Stockholders’ Agreement, as amended hereby, the following terms shall have the following respective meanings: 
 “Certificate of Incorporation” shall mean the Company’s Second Amended and Restated Certificate of Incorporation, as
filed with the Secretary of State of Delaware on or prior to the Series R Closing Date, as amended from time to time. 
 “Investors” shall mean the Series B Holders, the Series C Holders and the Purchasers, and with respect to only Sections 2.1 through 2.13 of this Agreement (and with respect to any terms used within
Sections 2.1 through 2.13 hereof that, by definition, include the “Investors” and solely with respect to the use of such terms in such Sections) and with respect to Section 7.1 of this Agreement the term “Investors”
shall also include the Series R Holder. 
 “Majority Investors” shall mean those holders of a majority
of the Registrable Securities issued or issuable to the Investors upon conversion of outstanding Series B Stock, Series C Stock, Series D Stock, Series R Stock and Series R-1 Stock; provided, however, that with respect to
Section 3.10 of this Agreement and with respect to Section 7.1 of this Agreement (solely as Section 7.1 relates to amendments and waivers of this Agreement that do not include amendments or waivers of the rights granted to the
Series R Holder pursuant to this Agreement), the term “Majority Investors” shall not include the holders of Registrable Securities issued or issuable upon conversion of any Series R Stock or Series R-1 Stock. 
 “New Shares” shall mean (a) any Common Stock or Preferred Stock or other equity securities of the Company whether
now authorized or not, (b) any rights, options, or warrants to purchase said shares, and (c) securities of any type whatsoever that are, or may become, convertible into, exercisable, exchangeable, or carrying rights to subscribe for any
equity securities of the Company (collectively with the securities referred to in clause (b) above, “Options”); provided, however, that “New Shares” does not include (i) securities offered to the public pursuant
to a registration statement filed under the Securities Act in connection with a 

  

 2 

 
Qualified IPO; (ii) securities issued pursuant to the acquisition of another Person by the Company by merger, consolidation, amalgamation, exchange of
shares, the purchase of substantially all of the assets or otherwise in a transaction that has been approved by the Majority Investors; (iii) up to 3,675,522 shares of Common Stock (appropriately adjusted to take account of any stock split,
stock dividend, combination of shares, recapitalization or other similar event) issuable to officers, directors, employees and consultants of the Company or a subsidiary pursuant to the exercise of options granted or shares of Common Stock directly
issued under the Equity Incentive Plan and such options and other rights to acquire Common Stock granted thereunder; (iv) securities issued to the Company’s stockholders in connection with any share split, share dividend, recapitalization,
split-up, subdivision or other similar event; (v) shares of Common Stock issued upon conversion of Preferred Stock; (vi) any shares of Common Stock issued to Emory University pursuant to Section 1.3 of that certain Stock Purchase
Agreement dated December 10, 1998, between Emory University and the Company; (vii) shares of Common Stock or Preferred Stock issued pursuant to rights of first refusal, pre-emptive, anti-dilution or similar rights outstanding on the date
hereof; (viii) securities issued or deemed issued in connection with a strategic business transaction approved by a majority of the Board, including the representative (if any) of the Series D Stock designated by the Lead Purchaser as
contemplated by Section 3.1(a)(ii) of this Agreement; and (ix) the Warrants, the Series R-1 Warrants and all securities issued or issuable upon exercise, conversion, exchange or transfer of either the Warrants or the Series R-1
Warrants. 
 “Preferred Stock” shall mean the Series A Stock, the Series B Stock, the Series C
Stock, the Series D Stock, the Series D-1 Stock, the Series R Stock and the Series R-1 Stock authorized by the Certificate of Incorporation. 
 “Registrable Securities” shall mean (i) the Common Stock issued or issuable to any Investor pursuant to the
conversion of the Purchased Securities or to the Series R Holder pursuant to the conversion of the Series R Stock or the Series R-1 Stock, (ii) any Common Stock issued or issuable in respect of the shares contemplated by
clause (i) above upon any share split, share dividend, recapitalization, split-up, subdivision or other similar event, and (iii) Common Stock issued or issuable in replacement or exchange of any of the securities issued in clauses (i)
or (ii) above, provided however that shares of Common Stock that are Registrable Securities shall cease to be Registrable Securities (a) upon any sale pursuant to an effective registration statement or Rule 144 under the Securities
Act or (b) upon any transfer or assignment which does not comply with the requirements of Section 2.9 of this Agreement. 
 “Stockholders” shall mean the Existing Investors, the Existing Stockholders and the Series R Holder. 
 Other than the foregoing, the other terms defined in the Existing Stockholders’ Agreement (including in Section 1.1 thereof and Schedule 6 thereto) shall remain in full force and effect, as modified hereby. 
  

 3 

 The following definitions are hereby added to the Existing Stockholders’ Agreement: 
 “Series R Closing Date” shall have the meaning given to such term in Section 1.2 of this Joinder and Amendment
Agreement. 
 “Series R Holder” shall mean Hoffmann-La Roche Inc. 
 “Series R Stock” shall mean the Series R Preferred Stock of the Company, par value $0.001 per share.

 “Series R-1 Stock” shall mean the Series R-1 Preferred Stock of the Company, par value $0.001
per share. 
 “Series R-1 Warrants” shall mean the Warrant(s) to Purchase Shares of Preferred Stock of
Pharmasset, Inc. that are issued by the Company to Roche on the Series R Closing Date with respect to an aggregate of 470,588 shares of Series R-1 Preferred Stock, together with all warrants issued in replacement or substitution thereof,
including, without limitation, balance warrants issued upon the partial exercise of such warrants. 
 1.2 Effect. This Joinder and
Amendment Agreement shall come into effect forthwith upon the closing of the purchase by the Series R Holder of the Series R Stock pursuant to the Series R Purchase Agreement (the date of such closing being the “Series R
Closing Date”). This Joinder and Amendment Agreement and the Certificate of Incorporation filed in connection with the closing of the transactions contemplated by the Series R Purchase Agreement amend in certain respects the Existing
Stockholders’ Agreement, the existing Amended and Restated Certificate of Incorporation of the Company and all other prior agreements between the Company and any one or more of the Stockholders with respect to the subject matter hereof and
thereof. Without limiting the generality of the foregoing, upon the effectiveness of this Joinder and Amendment Agreement, the Existing Stockholders’ Agreement shall be amended to include the Series R Holder as a Stockholder thereunder,
and the Parties agree that the Series R Holder shall be entitled to such rights and benefits of, and shall be subject to the same obligations, restrictions and terms applicable to, the Stockholders party thereto generally, as if the
Series R Holder was an original signatory thereto as a Stockholder, all as specifically set forth herein and therein. 
 SECTION 2. AMENDMENT
AND JOINDER TO REGISTRATION RIGHTS. 
 2.1 Amendment to Section 2.11. Section 2.11 of the Existing Stockholders’
Agreement is hereby deleted and replaced by the following: 
 “2.11 Other Registration Rights. The Company shall not grant to any
Person any registration rights more favorable than or inconsistent with any of those contained herein without the consent of the holders of at least 66 2/3% of the outstanding Registrable Securities, so long as any of the registration rights under
this Agreement remain in effect.” 
  

 4 

 2.2 Joinder of Series R Holder as “Investor”. From and after the
Series R Closing Date, the Parties agree that the Series R Holder shall be deemed to be an “Investor” solely under Sections 2.1 through 2.13 (inclusive) of the Existing Stockholders’ Agreement and with respect to
Section 7.1 of the Existing Stockholders’ Agreement, and shall be entitled to all the rights and benefits of, and subject to the obligations, restrictions and terms applicable to, an Investor under such Sections 2.1 through 2.13
(inclusive) and Section 7.1 of the Existing Stockholders’ Agreement. The Series R Holder shall not be deemed to be a “Investor” for any other purpose or under any Section or provision of the Existing Stockholders’
Agreement other than Section 2.1 through 2.13 (inclusive) and Section 7.1 of the Existing Stockholders’ Agreement. 
 SECTION 3. VOTING
AGREEMENT AND INFORMATION RIGHTS. 
 3.1 Voting Agreement. From and after the Series R Closing Date, until otherwise
designated in writing by the Existing Investors who hold, at such time, a majority of the Registrable Securities held by all Existing Investors, the Series R Holder shall vote all of the voting securities of the Company (including the Preferred
Stock and the Common Stock) over which such Series R Holder has voting control, shall take all other necessary or desirable actions within its control (whether in its capacity as a stockholder or otherwise, and including, without limitation,
attendance at meetings in person or by proxy for purposes of obtaining a quorum and execution of written consents or resolutions in lieu of meetings) and shall otherwise be subject to the obligations and agreements of a “Stockholder”
pursuant to Sections 3.1, 3.2 and 5.4 of the Existing Stockholders’ Agreement, as amended hereby. 
 3.2 Information Rights.
In lieu of all other information, inspection and other similar rights set forth in the Existing Stockholders’ Agreement, including, without limitation, those set forth in Sections 3.3 and 3.4 of the Existing Stockholders’ Agreement,
so long as the holders of the Series R Stock hold at least twenty-five percent (25%) of the number of shares of Series R Stock (as adjusted for stock splits, reverse splits, combinations, stock dividends and similar events) held immediately
after the closing of the transactions contemplated by the Series R Purchase Agreement, the Company shall deliver to each holder of Series R Stock (subject to the terms of Section 3.2(d) below): 
 (a) At least sixty (60) days prior to the commencement of each new fiscal year, projected financial statements for such fiscal year;

 (b) Within one hundred twenty (120) days after the close of each fiscal year of the Company, commencing with the
fiscal year ending on December 31, 2004, an audited consolidated balance sheet and statements of income and retained earnings and of cash flows of the Company and its Subsidiaries for the year then ended, audited by an accounting firm selected
by the Board, which annual financial statements shall show the financial position of the Company and such Subsidiaries on a consolidated basis as of the close of such fiscal year and the results of the Company’s and such Subsidiaries’
consolidated operations during such fiscal year; and 
 (c) Within thirty (30) days after the end of each fiscal quarter,
unaudited financial statements reflecting the Company’s most recent fiscal quarter, including a report reflecting the 

  

 5 

 
Company’s performance for such quarter as compared to the Company’s projected budget for such quarter. 
 (d) Notwithstanding the provisions of this Section 3.2, (i) the Company shall not be obligated to furnish or allow access to
information to any transferee of any holder of Series R Stock unless such transferee holds (or will hold immediately following such transfer) not less than 150,000 shares of Series R Stock (as adjusted for stock splits, reverse splits,
combinations, stock dividends or similar events) and each such transferee shall have agreed in writing to be bound by the provisions of the Existing Stockholders’ Agreement, as amended hereby, and (ii) the terms of Sections 3.3
through 3.10 (inclusive) of the Existing Stockholders’ Agreement shall not be deemed to be amended by this Joinder and Amendment Agreement and such Sections shall continue in full force and effect with respect to the Company and the Existing
Investors and Existing Stockholders. 
 3.3 Termination. The rights granted pursuant to this Section 3 may not be transferred to
any Person (other than an Affiliate of the Series R Holder) without the prior written consent of the Company and shall terminate (a) immediately prior to the consummation of an initial public offering of the Company’s Common Stock,
(b) immediately upon the filing of the first annual or quarterly report filed by the Company after it otherwise becomes subject to the reporting requirements of the Securities Exchange Act of 1934, as amended, or (c) immediately upon any
acquisition, merger, consolidation or other similar transaction as a result of which the Stockholders receive principally cash or publicly traded securities, whichever of (a), (b) or (c) is the first to occur. 
 SECTION 4. CONFIDENTIALITY 
 4.1
Confidentiality. The Series R Holder hereby expressly acknowledges, assumes and agrees to abide by the obligations, agreements and terms of Section 6.1 of the Existing Stockholders’ Agreement, including Schedule 6 to such
Existing Stockholders’ Agreement (collectively, the “Confidentiality Provisions”) as modified by the following sentence, as if such Confidentiality Provisions were expressly set forth in their entirety in this Joinder and
Amendment Agreement. 
 4.2 Enforcement. The Company and the Series R Holder agree that the covenants set forth in Section 6
(including Schedule 6) of the Existing Stockholders’ Agreement and this Section 4 shall be enforced to the fullest extent permitted by law. 
 4.3 Transferees. Each and every transferee or assignee of shares from the Series R Holder shall be bound by and subject to all the terms and conditions of this Section 4 (including the terms of
Section 6.1 and Schedule 6 of the Existing Stockholders’ Agreement incorporated herein). So long as the provisions of this Section 4 (including the terms of Section 6.1 and Schedule 6 of the Existing Stockholders’
Agreement incorporated herein) are in effect, the Company shall require, as a condition precedent to the transfer of any shares held by the Series R Holder, that the transferee agrees in writing to be bound by, and subject to, the terms and
conditions of this Section 4 (including the terms of Section 6.1 and Schedule 6 of the Existing Stockholders’ Agreement incorporated herein) as provided in this Section 4 (including the terms 

  

 6 

 
of Section 6.1 and Schedule 6 of the Existing Stockholders’ Agreement incorporated herein) and to ensure that his transferees of such shares
shall be likewise bound. 
 SECTION 5. MISCELLANEOUS 
 5.1 Amendment to Schedule A. Schedule A to the Existing Stockholders’ Agreement is hereby amended and restated as set forth on Schedule A attached to this Joinder and Amendment
Agreement. All references to Schedule A in the Existing Stockholders’ Agreement shall hereafter be deemed to refer to Schedule A attached hereto. 
 5.2 Incorporation of Miscellaneous Provisions. The provisions of Sections 7.1 (Waivers and Amendments), 7.3 (Successors and Assigns), 7.5
(Notices), 7.6 (Severability), 7.7 (Titles and Subtitles), 7.8 (Counterparts) and 7.9 (Equitable Remedies) of the Existing Stockholders’ Agreement are hereby incorporated in this Joinder and Amendment Agreement as if set forth in their entirety
herein (with references to “this Agreement” in such Sections being deemed to refer to this Joinder and Amendment Agreement). 
 5.3 Governing Law. This Joinder and Amendment Agreement shall be governed by and construed under the laws of the State of Delaware (without giving effect to any conflicts or choice of laws provisions which would cause the application
of the domestic substantive laws of any other jurisdiction). 
 5.4 Entire Agreement. The Existing Stockholders’ Agreement, as
amended by this Joinder and Amendment Agreement, constitutes the full and entire understanding and agreement between the Parties with regard to the subjects hereof and thereof. 
 5.5 Affiliate Shares. For purposes of determining the availability of rights and obligations of the Series R Holder hereunder and under the
Existing Stockholders’ Agreement, as amended hereby, unless otherwise provided, all shares of the Preferred Stock held by Affiliates of such Series R Holder (as determined pursuant to Section 2.9 of the Existing Stockholders’
Agreement, as amended hereby) shall be aggregated. 
 5.6 Company Obligations Excused in Certain Cases. Notwithstanding anything
contained herein to the contrary, the Company shall not be obligated to offer, sell or issue to any Person any Shares or take any other action otherwise required under the Existing Stockholders’ Agreement, as amended hereby, at any time if such
Person does not satisfy the representations and warranties set forth in Article IV of the Series R Purchase Agreement with respect to such offer, sale, issuance and securities or if such action would otherwise be considered to cause a
violation of Section 5 of the Securities Act or any other applicable securities laws relating to the issuance of securities by the Company. 
 [Signatures On Following Pages] 
  

 7 

 IN WITNESS WHEREOF, the parties hereto have executed this First Amendment and Joinder to Second Amended
and Restated Stockholders’ Agreement as of the date set forth in the first paragraph hereof. 
  
  

																	
	COMPANY:	  		  		  		  		  		 	SERIES R HOLDER:
							
	PHARMASSET, INC.	  		  		  		  		  		 	HOFFMANN-LA ROCHE INC.
									
	By:	  	/s/ Raymond F. Schinazi	  		  		  		  		  		 	 By:
	  	/s/Dennis E. Burns
	Name:	  	Raymond F. Schinazi	  		  		  		  		  		 	Name:	  	Dennis E. Burns
	Title:	  	Chairman	  		  		  		  		  		 	Title:	  	Vice President, Global Head of Business Development
	Address:	  	  	  		  		  		  		  		 	Address:	  	  
		  	  	  		  		  		  		  		 		  	  
		  	  	  		  		  		  		  		 		  	  
		  	Telecopier:____________________________	  		  		  		  		  		 		  	Telecopier:___________________________
								
		  		  		  		  		  		  		 	EXISTING INVESTORS:
								
		  		  		  		  		  		  		 	 BURRILL LIFE SCIENCES
 CAPITAL
FUND, L.P.

									
		  		  		  		  		  		  		 	 By:
	  	 Burrill & Company (Life Sciences GP), LLC, its general partner

									
		  		  		  		  		  		  		 	 By:
	  	 /s/ G. Steven Burrill

		  		  		  		  		  		  		 	 Name:
	  	 G. Steven Burrill

		  		  		  		  		  		  		 	 Title:
	  	 Managing Member

								
		  		  		  		  		  		  		 	 BURRILL INDIANA LIFE SCIENCES
 CAPITAL FUND, L.P.

									
		  		  		  		  		  		  		 	 By:
	  	 Burrill and Company (Indiana GP), LLC, its general Partner

									
		  		  		  		  		  		  		 	 By:
	  	 /s/ G. Steven Burrill

		  		  		  		  		  		  		 	 Name:
	  	 G. Steven Burrill

		  		  		  		  		  		  		 	 Title:
	  	 Managing Member

  
  

 [Signature Page to First Amendment and Joinder Agreement] 

			
	EXISTING INVESTORS (Cont’d):
	
	MPM BIOVENTURES III, L.P.
		
	 By:
	 	MPM BioVentures III GP, L.P., its General
	 Partner

		
	 By:
	 	MPM BioVentures III LLC, its General Partner

  

			
	 By:
	 	 /s/ Luke Evnin

	 Name:
	 	 Luke Evnin

	 Title:
	 	 Series A Member

  

			
	
	BB BIOVENTURES L.P.
		
	 By:
	 	BAB BioVentures L.P., its
	 General Partner

		
	 By:
	 	BAB BioVentures, N.V., its
	 General Partner

  

			
	 By:
	 	 /s/ Ansbert K. Gädicke

	 Name:
	 	 Ansbert K. Gädicke, M.D.

  

			
	
	MPM BIOVENTURES PARALLEL FUND, L.P.
		
	 By:
	 	MPM BioVentures I LP, its General Partner
		
	 By:
	 	MPM BioVentures I LLC, its
	 General Partner

  

			
	 By:
	 	 /s/ Ansbert K. Gädicke

	 Name:
	 	 Ansbert K. Gädicke, M.D.

	 Title:
	 	 Manager

  

			
	
	 MPM ASSET MANAGEMENT
 INVESTORS
1999 LLC

		
	 By:
	 	/s/ Ansbert K. Gädicke
	 Name:
	 	 Ansbert K. Gädicke, M.D.

	 Title:
	 	 Manager

  

 [Signature Page to First Amendment and Joinder Agreement] 

			
	EXISTING INVESTORS (Cont’d):
	
	MPM BIOVENTURES III-QP, L.P.
		
	 By:
	 	MPM BioVentures III GP, L.P., its
	 General Partner

		
	 By:
	 	MPM BioVentures III LLC, its
	 General Partner

  

			
	 By:
	 	 /s/ Luke Evnin

	 Name:
	 	 Luke Evnin

	 Title:
	 	 Series A Member

  

			
	
	 MPM BIOVENTURES III GMBH & CO.
 BETEILIGUNGS KG

		
	 By:
	 	MPM BioVentures III GP, L.P., in its
	 capacity as the Managing Limited Partner

		
	 By:
	 	MPM BioVentures III LLC, its
	 General Partner

  

			
	 By:
	 	 /s/ Luke Evnin

	 Name:
	 	 Luke Evnin

	 Title:
	 	 Series A Member

  

			
	
	 MPM BIOVENTURES III PARALLEL
 FUND,
L.P.

		
	 By:
	 	MPM BioVentures III GP, L.P., its
	 General Partner

		
	 By:
	 	MPM BioVentures III LLC, its
	 General Partner

  

			
	 By:
	 	 /s/ Luke Evnin

	 Name:
	 	 Luke Evnin

	 Title:
	 	 Series A Member

  

			
	
	 MPM ASSET MANAGEMENT
 INVESTORS
2004 BVIII LLC

		
	 By:
	 	/s/ Luke Evnin
	 Name:
	 	 Luke Evnin

	 Title:
	 	 Series A Member

  

 [Signature Page to First Amendment and Joinder Agreement] 

			
	EXISTING INVESTORS (Cont’d):
	
	 TVM V LIFE SCIENCE VENTURES
 GMBH & CO. KG

		
	 By:
	 	/s/ Gert Caspritz
	 Name:
	 	 Gert Caspritz

	 Title:
	 	 Managing Limited Partner

  

			
		
	 By:
	 	/s/ David Poltack
	 Name:
	 	 David Poltack

	 Title:
	 	 Managing Limited Partner

  

			
	
	TVM IV GMBH & CO. KG
		
	 By:
	 	/s/ Gert Caspritz
	 Name:
	 	 Gert Caspritz

	 Title:
	 	 Managing Limited Partner

  

			
		
	 By:
	 	/s/ David Poltack
	 Name:
	 	 David Poltack

	 Title:
	 	 Managing Limited Partner

  

 [Signature Page to First Amendment and Joinder Agreement] 

			
	EXISTING INVESTORS (Cont’d):
	
	 MDS LIFE SCIENCES TECHNOLOGY
 FUND
II NC LIMITED PARTNERSHIP

		
	 By:
	 	MDS LSTF II (NCGP) Inc., its General Partner
		
	 By:
	 	 /s/ Graysanne Bedell

	 Name:
	 	 Graysanne Bedell, Secretary

	 Title:
	 	 Greg Gubitz, Vice-President

  

			
	
	 MDS LIFE SCIENCES TECHNOLOGY
 FUND
II QUEBEC LIMITED
 PARTNERSHIP

		
	 By:
	 	MDS LSTF II (QGP) Inc., its General Partner
		
	 By:
	 	 /s/ Graysanne Bedell

	 Name:
	 	 Graysanne Bedell, Secretary

	 Title:
	 	 Greg Gubitz, Vice-President

  

			
	
	MLII CO-INVESTMENT FUND NC LIMITED PARTNERSHIP
		
	 By:
	 	MLII (NCGP) Inc., its General Partner
		
	 By:
	 	 /s/ Graysanne Bedell

	 Name:
	 	 Graysanne Bedell, Secretary

	 Title:
	 	 Greg Gubitz, Vice-President

  

 [Signature Page to First Amendment and Joinder Agreement] 

			
	
	CDIB BIOSCIENCE VENTURES I, INC.
		
	 By:
	 	 /s/ Benny T. Hu

		 	 Benny T. Hu

  

 [Signature Page to First Amendment and Joinder Agreement] 

	
	
	EXISTING STOCKHOLDERS:
	
	 /s/ Raymond F. Schinazi, Ph.D.

	 Raymond F. Schinazi, Ph.D.

  

	
	
	 /s/ Chung K. Chu, Ph.D.

	 Chung K. Chu, Ph.D.

  

	
	
	 /s/ Dennis Liotta, Ph.D.

	 Dennis Liotta, Ph.D.

  

	
	
	 /s/ Jean-Pierre Sommadossi, Ph.D.

	 Jean-Pierre Sommadossi, Ph.D.

  

	
	
	 /s/ Carol Lynn Schinazi

	 Carol Lynn Schinazi

  

	
	
	 /s/ Rebecca Elizabeth Schinazi

	 Rebecca Elizabeth Schinazi

  

	
	
	 /s/ Jaclyn H. Chu

	 Jaclyn H. Chu

  

	
	
	 /s/ Susan Chu Walley

	 Susan Chu Walley

  

 [Signature Page to First Amendment and Joinder Agreement] 

 Schedule A 
  

							
	 Stockholder’s Name and Address
	  	Number of
Common
Shares Held	  	Number and Series of
Preferred Shares Held	  	 Number of
Series D-1 or
 R-1 Warrants
Held

	 Purchasers:
	  		  		  	
	 Burrill Life Sciences Capital Fund, L.P.
	  	None	  	1,764,775 Series D
Preferred	  	264,716
D-1 Warrants
	 Burrill Indiana Life Sciences Capital Fund, L.P.
	  	None	  	392,172 Series D
Preferred	  	58,826
D-1 Warrants
	 Address for each of the above 2 entities:
	  		  		  	
	 One Embarcadero Center, Suite 2700
 San Francisco, CA 94111
 Telecopy No.: (415) 591-5401
	  		  		  	
				
	 with a copy to:
	  		  		  	
	 Richard Peers, Esq.
 Heller Ehrman White & McAuliffe LLP
 275 Middlefield Road
 Menlo Park, CA 94025
 Telecopy No.: (650) 324-0638
	  		  		  	
				
	 BB BioVentures L.P.
	  	None	  	348,585 Series D
Preferred	  	52,288
D-1 Warrants
	 MPM BioVentures Parallel Fund, L.P.
	  	None	  	39,573 Series D
Preferred	  	5,936
D-1 Warrants
	 MPM Asset Management Investors 1999 LLC
	  	None	  	4,079 Series D
Preferred	  	612
D-1 Warrants
	 MPM BioVentures III, L.P.
	  	None	  	120,288 Series D
Preferred	  	18,043
D-1 Warrants
	 MPM BioVentures III-QP, L.P.
	  	None	  	1,788,843 Series D
Preferred	  	268,327
D-1 Warrants
	 MPM BioVentures III GmbH & Co. Beteiligungs KG
	  	None	  	151,175 Series D
Preferred	  	22,676
D-1 Warrants
	 MPM BioVentures III Parallel Fund, L.P.
	  	None	  	54,029 Series D
Preferred	  	8,104
D-1 Warrants

							
	 Stockholder’s Name and Address
	  	Number of
Common
Shares Held	  	Number and Series of
Preferred Shares Held	  	Number of
Series D-1 or
R-1 Warrants
Held
	 MPM Asset Management Investors 2004 BVIII LLC
	  	None	  	42,527 Series D
Preferred	  	6,379
D-1 Warrants
	 Address for each of the above 8 entities:
	  		  		  	
	 c/o MPM Asset Management LLC
 111 Huntington Avenue
 31st Floor
 Boston, MA 02199
 Telephone: (617) 425-9200
 Telecopy: (617) 425-9201
	  		  		  	
				
	 TVM V Life Science Ventures GmbH &
 Co. KG
	  	None	  	980,423 Series D
Preferred	  	147,064
D-1 Warrants
	 c/o TVM Management Corporation
 Attn: Mark G. Cipriano
 101 Arch Street, Suite 1950
 Boston, MA 02110
 Telecopy No.: (617) 345-9377
	  		  		  	
				
	 with a copy to:
	  		  		  	
	 c/o TVM Techno Venture Mgmt GmbH
 & Co. KG
 Attn: Bernd Seibel
 Maximilianstr. 35
 Entrance C
 80539 Munich, Germany
 Telecopy: No.: 011 49 89 998992 55
	  		  		  	
				
	 MDS Life Sciences Technology Fund II
 NC Limited Partnership
	  		  	869,992 Series D
Preferred	  	130,499
D-1 Warrants
	 100 International Blvd.
 Toronto, Ontario
 M9W 6J6
	  		  		  	
				
	 with a copy to:
	  		  		  	
	 Legal Department
 MDS Capital Corp.
 100 International Blvd.
 Toronto, Ontario
 M9W 6J6
 Telecopy No.: (416) 213-4232
	  		  		  	

							
	 Stockholder’s Name and
Address
	  	Number of
Common
Shares Held	  	Number and Series of
Preferred Shares Held	  	Number of
Series D-1 or
R-1 Warrants
Held
	 MDS Life Sciences Technology Fund II
 Quebec Limited Partnership
	  		  	306,515 Series D
Preferred	  	45,977
D-1 Warrants
	 2000 Peel Street
 Suite 560
 Montreal, Quebec
 H3A 2W5
	  		  		  	
				
	 with a copy to:
	  		  		  	
	 Legal Department
 MDS Capital Corp.
 100 International Blvd.
 Toronto, Ontario
 M9W 6J6
 Telecopy No.: (416) 213-4232
	  		  		  	
				
	 MLII Co-Investment Fund NC Limited Partnership
	  		  		  	
	 100 International Blvd.
 Toronto, Ontario
 M9W 6J6
	  		  	392,169 Series D
Preferred	  	58,825
D-1 Warrants
				
	 with a copy to:
	  		  		  	
	 Legal Department
 MDS Capital Corp.
 100 International Blvd.
 Toronto, Ontario
 M9W 6J6
 Telecopy No.: (416) 213-4232
	  		  		  	
				
	 CDIB BioScience Ventures I, Inc.
	  		  		  	
	 c/o CDIB BioScience Venture
 Management, Inc.
 Attn: Tai-Sen Soong
 30th Floor, 99 Tun Hwa South Rd.,
 Section 2
 Taipei, Taiwan
 Telecopy No.: 011 886 2 2325 0557
	  		  	588,235 Series D
Preferred	  	88,235
D-1 Warrants
				
	 with a copy to:
	  		  		  	
	 CDIB BioScience Ventures I, Inc.,
 c/o CDIB BioScience Venture
 Management, Inc.
 Attn: Grace Yu
 9191 Towne Centre Drive, Suite 575
 San Diego, CA 92122
 Telecopy No.: (858) 552-6811
	  		  		  	

							
	 Stockholder’s Name and Address
	  	Number of
Common
Shares Held	  	Number and Series of
Preferred Shares Held	 	 Number of
Series D-1 or
 R-1 Warrants
 Held

	 Series C Holders:
	  		  		 	
	 TVM IV GmbH & Co. KG
	  		  		 	
	 c/o TVM Management Corporation
 Attn: Mark G. Cipriano
 101 Arch Street, Suite 1950
 Boston, MA 02110
 Telecopy No.: (617) 345-9377
	  		  	1,357,798 Series C
Preferred	 	78,453
D-1 Warrants
				
	 with a copy to:
	  		  		 	
	 c/o TVM Techno Venture Mgmt GmbH
 & Co. KG
 Attn: Bernd Seibel
 Maximilianstr. 35
 Entrance C
 80539 Munich, Germany
 Telecopy No.: 011 49 89 998992 55
	  		  		 	
				
	 Series B Holders:
	  		  		 	
				
	 BB BioVentures L.P.
	  		  	2,300,000 Series B	 	See Above
		  		  	Preferred	 	
	 MPM BioVentures Parallel Fund, L.P.
	  		  	and 500,000
Series A Preferred
(collectively)	 	See Above
	 MPM Asset Management Investors 1999
 LLC
	  		  		 	
				
	 each c/o MPM Asset Management LLC
 111 Huntington Avenue
 31st Floor
 Boston, MA 02199
 Telephone: (617) 425-9200
 Telecopy: (617) 425-9201
	  		  		 	
				
	 Series R Holder:
  
 Hoffmann-La Roche Inc.
	  		  	
 400,000 Series R
	 	470,588
	 340 Kingsland Street
 Nutley, NJ 07110-1199
 Attn: General Counsel
 Telecopy No.: (973) 235-3500
	  		  	Preferred	 	R-1 Warrants
				
	 with a copy to:
	  		  		 	
	 F. Hoffmann-La Roche Ltd.
 Grenzacherstrasse 124/Bldg 21-292
 CH-4070 Basel
 Switzerland
 Attn: Carole L. Nuechterlein
 Telecopy No.: + 41 61 688 4169
	  		  		 	

							
	 Stockholder’s Name and Address
	  	Number of
Common
Shares Held	  	Number and Series of
Preferred Shares Held	  	 Number of
Series D-1 or
 R-1 Warrants
 Held

	 Restricted Stockholders:
 Raymond F. Schinazi, Ph.D.
 2881 Peachtree Road, Apt. #2204
 Atlanta, GA 30305
	  	3,495,556	  	320,500 Series A
Preferred	  	None
				
	 Chung K. Chu, Ph.D.
 115 Cedar Springs Place
 Athens, GA 30605
	  	740,224	  	50,000 Series A
Preferred	  	None
				
	 Dennis C. Liotta, Ph.D.
 2809 Payton Oaks Drive
 Atlanta, GA 30345
	  	500,000	  	5,000 Series A
Preferred	  	None
				
	 Jean-Pierre Sommadossi, Ph.D.
 7 Lowell Street
 Cambridge, MA 02138
	  	500,000	  	50,000 Series A
Preferred	  	None
				
	 Carol Lynn Schinazi
 c/o Raymond F. Schinazi, Ph.D
 2881 Peachtree Road, Apt. #2204
 Atlanta, GA 30305
	  	100,000	  	None	  	None
				
	 Rebecca Elizabeth Schinazi
 c/o Raymond F. Schinazi, Ph.D
 2881 Peachtree Road, Apt. #2204
 Atlanta, GA 30305
	  	104,444	  	None	  	None
				
	 Jaclyn H. Chu
 2124 Pine Street, Unit 2F
 Philadelphia, PA 19103
	  	4,888	  	30,000 Series A
Preferred	  	None
				
	 Susan Chu Walley
 1625 Woodfern Drive
 Birmingham, AL 35209
	  	4,888	  	30,000 Series A
Preferred	  	None

 Exhibit A 
 Existing Stockholders’ Agreement 
 (Please refer to Exhibit 4.6 to the S-1, 
 Second Amended and Restated Stockholders’ Agreement, 
 dated as of August 4, 2004.)Waiver Agreement and Second Amendment to Amended and Restated Stockholders' Agmt

 EXHIBIT 4.7 
 EXECUTION COPY 
 WAIVER AGREEMENT AND SECOND AMENDMENT TO THE 
 SECOND AMENDED AND RESTATED STOCKHOLDERS’ AGREEMENT 
 THIS WAIVER AGREEMENT AND SECOND AMENDMENT (the “Waiver and Amendment”) TO THE SECOND AMENDED AND RESTATED STOCKHOLDERS’ AGREEMENT dated as of August 4, 2004, as amended (the
“Stockholders’ Agreement”), is entered into as of February 14, 2006 by and among Pharmasset, Inc., a Delaware corporation (the “Company”), and the undersigned holders of the Company’s capital stock
(collectively, the “Stockholders”). Capitalized terms used but not otherwise defined in this Waiver and Amendment shall have the meanings set forth in the Stockholders’ Agreement. 
 RECITALS 
 WHEREAS, Dr. Raymond F.
Schinazi (“Dr. Schinazi”) has requested that the Company record the transfer of 2,000,000 shares of the Company’s Common Stock, par value $0.001 (the “Transfer Shares”) from Dr. Schinazi as follows:
(i) 1,000,000 shares to RFS Partners, L.P., a Georgia limited partnership (the “Partnership”), and (ii) 1,000,000 shares to Raymond F. Schinazi 2005 Qualified Annuity Trust, a Georgia trust (the “Trust”);

 WHEREAS, the above described transfers of the Transfer Shares (the “Schinazi Transfers”) may not meet all the conditions
for an exception to the restrictions on transfer provided in Section 5(b) of the Stockholders’ Agreement; and 
 WHEREAS, the
Stockholders hereby desire to grant a waiver of their right of first refusal and right of co-sale pursuant to Sections 5.2 and 5.3 of the Stockholders’ Agreement with respect to the Schinazi Transfers; 
 WHEREAS, the Company and the Stockholders desire to amend Sections 1.1, 4.1, 5.2 and 7.1 of the Stockholders’ Agreement; 
 NOW, THEREFORE, in consideration of the mutual promises and covenants hereinafter set forth, the receipt, sufficiency and adequacy of which are hereby
acknowledged, the parties hereto agree to amend the Stockholders’ Agreement as follows: 
 1.1 Waiver. 
 (a) Solely with respect to the Schinazi Transfers, each of the undersigned hereby waives its respective rights under Sections 5.2 and 5.3
of the Stockholders’ Agreement, including any right to notice; provided that the Partnership and the Trust each agrees in writing to be bound by the obligations of the Stockholders’ Agreement pursuant to the Joinder Agreement
between the Company and the Partnership and the Joinder Agreement between the Company and the Trust, respectively, each to be entered into concurrently as of the Effective Date of this Waiver and Amendment (collectively, the “Joinder
Agreements”). 

 WAIVER AGREEMENT AND SECOND
AMENDMENT TO THE 
 SECOND AMENDED AND
RESTATED STOCKHOLDERS’ AGREEMENT 

 (b) Solely with respect to the Transfer Shares, each of the undersigned hereby waives the
conditions to transfer of the rights to participate in registrations granted to Stockholders other than Investors under Section 2.2 of the Stockholders’ Agreement as they may be applicable to the Trust and the Partnership and agree and
acknowledge that the Trust and the Partnership shall have the same rights to participate in registrations granted to the other Stockholders under Sections 2.2 and 2.9, provided that the Partnership and the Trust each agrees in writing to be
bound by the obligations of the Stockholders’ Agreement pursuant to the Joinder Agreements. 
 1.2 Amendments. 
 (a) The Stockholders’ Agreement is hereby amended by inserting the following definition in Section 1.1 immediately following the
definition of “Sale of the Company”: 
 “Schinazi Transferees” shall mean RFS Partners, L.P., a
Georgia limited partnership, and Raymond F. Schinazi 2005 Qualified Annuity Trust, a Georgia trust. 
 (b) The
Stockholders’ Agreement is hereby amended by deleting paragraph (a) of Section 4.1 and replacing it in its entirety with the following: 
 (a) “In the event the Company desires to issue any New Shares, it shall first deliver to each Investor, Dr. Raymond Schinazi and the Schinazi Transferees (each such Person being referred to in this
Section 4 as a “Buyer”) a written notice (the “Notice of Proposed Issuance”) specifying the type and total number of such New Shares which the Company then desires to issue (the “Offered New Shares”), all of the
terms, including the price, upon which the Company proposes to issue the Offered New Shares, and stating that the Buyers shall have the right to purchase the Offered New Shares in the manner specified in this Section 4.1 at the price and in
accordance with the terms and provisions specified in such Notice of Proposed Issuance.” 
 (c) The Stockholders’
Agreement is hereby amended by deleting paragraph (d) of Section 4.1 in its entirety. 
 (d) The Stockholders’
Agreement is hereby amended by changing the reference to paragraphs (a)-(d) in paragraph (e) in Section 4.1 to “paragraphs (a)-(c)”. 
 (e) The Stockholders’ Agreement is hereby amended by changing the designation of paragraph (e) in Section 4.1 to
“(d)” and by changing the designation of paragraph (f) in Section 4.1 to “(e)”. 
  

 2 
 WAIVER AGREEMENT AND SECOND AMENDMENT TO THE 
 SECOND AMENDED AND RESTATED STOCKHOLDERS’ AGREEMENT 

 (f) The Stockholders’ Agreement is hereby amended by deleting the first sentence of
paragraph (a) of Section 5.2 and replacing it in its entirety with the following: 
 “If at any time a Restricted Stockholder
(“Transferring Stockholder”) desires to Transfer his or its Common Shares or other equity securities of the Company, in each case, now owned or hereafter acquired, to a third party (the “Proposed Transferee”) and
such Transfer has been approved in accordance with Section 5.1(a) above, then notwithstanding that such approval was obtained, the Transferring Stockholder shall, at least thirty (30) days prior to any Transfer, submit a written offer (the
“Offer”) to sell such Common Shares or other securities of the Company (the “Offered Shares”) to the Investors, Dr. Raymond Schinazi and the Schinazi Transferees (collectively referred to as the
“Buyers” in this Section 5) on terms and conditions, including price, not less favorable to the Buyers than those on which the Transferring Stockholder proposes to Transfer such Offered Shares to the Proposed Transferee.”

 (g) The Stockholders’ Agreement is hereby amended by deleting Section 7.1 and replacing it in its entirety with
the following: 
 “7.1 Waivers and Amendments. The rights and obligations of the Company may not be waived (either
generally or in a particular instance, either retroactively or prospectively, and either for a specified period of time or indefinitely) or amended without the written consent of the Company. The rights and obligations of the Stockholders under this
Agreement may not be waived (either generally or in a particular instance, either retroactively or prospectively, and either for a specified period of time or indefinitely) or amended without the written consent of (i) the Majority Investors
and (ii) Stockholders other than the Investors holding a majority of the Common Shares and Preferred Shares (on an as-if-converted basis) owned by such Stockholders; provided, however, that any amendment or waiver that would only
affect the foregoing rights of an individual party hereto may be effected with only the written consent of such party. Upon the effectuation of each such waiver or amendment, the Company shall promptly give written notice thereof to the holders of
the shares who have not previously consented thereto in writing. 
 Notwithstanding the foregoing: 
 (A) an increase in the number of shares of Common Stock by not more than 1,600,000 shares (appropriately adjusted to take account of any
stock split, stock dividend, combination of shares, recapitalization or other similar event) as set forth in clause (iii) of the proviso to the definition of “New Shares” in Section 1.1 hereof may be approved upon the written
consent of (i) the Majority Investors and (ii) Stockholders holding a majority of the outstanding shares of the Common Stock that are subject to this Agreement and the Preferred Stock (on an as-if-converted basis) voting together as a
single class; provided that (x) such increase is approved by the Board of Directors of the Company and (y) the same increase 

  

 3 
 WAIVER AGREEMENT AND SECOND AMENDMENT TO THE 
 SECOND AMENDED AND RESTATED STOCKHOLDERS’ AGREEMENT 

 
is concurrently made to the number of shares of Common Stock set forth in clause (ii) of the definition of “Excluded Securities” in the
Certificate of Incorporation; 
 (B) a reduction in the minimum price per share at which Common Stock is required to be
offered to the public as set forth in the definition of “Qualified IPO” in Section 1.1 hereof, or the waiver of such minimum price per share requirement in its entirety, may be approved upon the written consent of (i) the
Majority Investors and (ii) Stockholders holding a majority of the outstanding shares of the Common Stock that are subject to this Agreement and the Preferred Stock (on an as-if-converted basis) voting together as a single class;
provided that the same reduction shall be concurrently made in the minimum price per share at which Common Stock is required to be offered to the public as set forth in the definition of “Qualified IPO” in the Certificate of
Incorporation; and 
 (C) any amendments to this Agreement of a conforming or ministerial nature necessary for purposes of
adding additional parties hereto or applying the provisions of this Agreement to the holders of shares of any additional series of capital stock that may issued by the Company in the future in connection with a bona fide capital raising transaction
or to a third party in connection with a bona fide corporate transaction may be approved upon the written consent of (i) the Majority Investors and (ii) Stockholders holding a majority of the outstanding shares of the Common Stock that are
subject to this Agreement and the Preferred Stock (on an as-if-converted basis) voting together as a single class; provided, however, that any amendment or waiver that would only affect the foregoing rights of an individual party hereto may be
effected with only the written consent of such party; and provided further that such shares are issued in compliance with the terms of this Agreement.” 
 1.3 Governing Law. This Waiver and Amendment shall be governed by and construed under the laws of the State of Delaware (without giving effect to any conflicts or choice of laws provisions which would
cause the application of the domestic substantive laws of any other jurisdiction). 
 1.4 Effective Date. This Waiver and
Amendment shall become effective as of the date first written above (the “Effective Date”) upon receipt by the Company of counterparts of this Waiver and Amendment duly executed by the Majority Investors and the Stockholders other than the
Investors holding a majority of the Common Shares and Preferred Shares (on an as-if-converted basis) owned by such Stockholders. Each Stockholder shall be bound by this Waiver and Amendment whether or not such Stockholder shall have consented to
this Waiver and Amendment. 
 1.5 Miscellaneous. From and after the Effective Date of this Waiver and Amendment, each reference
in the Stockholders Agreement to “this Agreement”, “hereof”, “hereunder”, or words of like import in any and all agreements, instruments, documents, notes, certificates and other writings of any kind and nature shall be
deemed to refer to the Stockholders Agreement as amended by this Waiver and Amendment. This Waiver and Amendment may be executed in any number of counterparts, each of which shall be an original, but all of which together constitute one instrument.
The headings in this Waiver and Amendment are for purposes of reference only and shall not limit or otherwise effect the meaning hereof. 
 [Signatures On Following Pages] 
  

 4 
 WAIVER AGREEMENT AND SECOND AMENDMENT TO THE 
 SECOND AMENDED AND RESTATED STOCKHOLDERS’ AGREEMENT 

 IN WITNESS WHEREOF, the parties hereto have executed this Second Amendment to the Second Amended and
Restated Stockholders’ Agreement as of the date set forth in the first paragraph hereof. 
  

									
	COMPANY:	 		 	STOCKHOLDERS:
			
	PHARMASSET, INC.	 		 	
		 		 		 	/s/ Raymond F. Schinazi
		 		 		 	Raymond F. Schinazi, Ph.D.
	By:	 	/s/ P. Schaefer Price	 		 	
	Name:	 	P. Schaefer Price	 		 	
	Title:	 	President and Chief Executive Officer	 		 	
		 		 		 	/s/ Chung K. Chu, Ph.D.
		 		 		 	Chung K. Chu, Ph.D.
				
		 		 		 	/s/ Dennis Liotta, Ph.D.
		 		 		 	Dennis Liotta, Ph.D.
				
		 		 		 	/s/ Jean-Pierre Sommadossi, Ph.D
		 		 		 	Jean-Pierre Sommadossi, Ph.D.
				
		 		 		 	/s/ Carol Lynn Schinazi
		 		 		 	Carol Lynn Schinazi
				
		 		 		 	/s/ Rebecca Elizabeth Schinazi
		 		 		 	Rebecca Elizabeth Schinazi
				
		 		 		 	/s/ Jaclyn H. Chu
		 		 		 	Jaclyn H. Chu
				
		 		 		 	/s/ Susan Chu Walley
		 		 		 	Susan Chu Walley

  

 5 
 WAIVER AGREEMENT AND SECOND AMENDMENT TO THE 
 SECOND AMENDED AND RESTATED STOCKHOLDERS’ AGREEMENT 

									
		 		 		 	STOCKHOLDERS (Cont’d):
				
		 		 		 	HOFFMANN-LA ROCHE INC.
					
		 		 		 	By:	 	/s/ Dennis E. Burns
		 		 		 	Name:	 	Dennis E. Burns
		 		 		 	Title:	 	Vice President
		 		 		 		 	 Global Head of Business Development

				
		 		 		 	BURRILL LIFE SCIENCES CAPITAL FUND, L.P.
				
		 		 		 	By: Burrill & Company (Life Sciences GP), LLC, its General Partner
					
		 		 		 	By:	 	/s/ G. Steven Burrill
		 		 		 	Name:	 	G. Steven Burrill
		 		 		 	Title:	 	Managing Member
				
		 		 		 	BURRILL INDIANA LIFE SCIENCES CAPITAL FUND, L.P.
				
		 		 		 	By: Burrill and Company (Indiana GP), LLC, its General Partner
					
		 		 		 	By:	 	G. Steven Burrill
		 		 		 	Name:	 	G. Steven Burrill
		 		 		 	Title:	 	 Managing Member

				
		 		 		 	MPM BIOVENTURES III, L.P.
				
		 		 		 	By: MPM BioVentures III GP, L.P., its General Partner
				
		 		 		 	By: MPM BioVentures III LLC, its General Partner
					
		 		 		 	By:	 	/s/ Ansbert Gadicke
		 		 		 	Name:	 	Ansbert Gadicke
		 		 		 	Title:	 	General Partner

  

 6 
 WAIVER AGREEMENT AND SECOND AMENDMENT TO THE 
 SECOND AMENDED AND RESTATED STOCKHOLDERS’ AGREEMENT 

									
		 		 		 	STOCKHOLDERS (Cont’d):
				
		 		 		 	BB BIOVENTURES L.P.
					
		 		 		 	By:	 	BAB BioVentures L.P., its General Partner
					
		 		 		 	By:	 	BAB BioVentures, N.V., its General Partner
					
		 		 		 	By:	 	/s/ Ansbert Gadicke
		 		 		 	Name:	 	Ansbert Gädicke, M.D.
		 		 		 	Title:	 	General Partner
				
		 		 		 	MPM BIOVENTURES PARALLEL FUND, L.P.
					
		 		 		 	By:	 	MPM BioVentures I LP, its General Partner
					
		 		 		 	By:	 	MPM BioVentures I LLC, its General Partner
					
		 		 		 	By:	 	/s/ Ansbert Gadicke
		 		 		 	Name:	 	Ansbert Gädicke, M.D.
		 		 		 	Title:	 	Manager
				
		 		 		 	MPM ASSET MANAGEMENT INVESTORS 1999 LLC
					
		 		 		 	By:	 	/s/ Ansbert Gadicke
		 		 		 	Name:	 	Ansbert Gädicke, M.D.
		 		 		 	Title:	 	Manager

  

 7 
 WAIVER AGREEMENT AND SECOND AMENDMENT TO THE 
 SECOND AMENDED AND RESTATED STOCKHOLDERS’ AGREEMENT 

									
		 		 		 	STOCKHOLDERS (Cont’d):
				
		 		 		 	MPM BIOVENTURES III-QP, L.P.
				
		 		 		 	By: MPM BioVentures III GP, L.P., its General Partner
				
		 		 		 	By: MPM BioVentures III LLC, its General Partner
		 		 		 	By:	 	/s/ Ansbert Gadicke
		 		 		 	Name:	 	Ansbert Gadicke
		 		 		 	Title:	 	General Partner
				
		 		 		 	MPM BIOVENTURES III GMBH & CO. BETEILIGUNGS KG
				
		 		 		 	By: MPM BioVentures III GP, L.P., in its capacity as the Managing Limited Partner
					
		 		 		 	By:	 	MPM BioVentures III LLC, its General Partner
					
		 		 		 	By:	 	/s/ Ansbert Gadicke
		 		 		 	Name:	 	Ansbert Gadicke
		 		 		 	Title:	 	General Partner
				
		 		 		 	MPM BIOVENTURES III PARALLEL FUND, L.P.
				
		 		 		 	By: MPM BioVentures III GP, L.P., its General Partner
				
		 		 		 	By: MPM BioVentures III LLC, its General Partner
					
		 		 		 	By:	 	/s/ Ansbert Gadicke
		 		 		 	Name:	 	Ansbert Gadicke
		 		 		 	Title:	 	General Partner

  

 8 
 WAIVER AGREEMENT AND SECOND AMENDMENT TO THE 
 SECOND AMENDED AND RESTATED STOCKHOLDERS’ AGREEMENT 

									
		 		 		 	STOCKHOLDERS (Cont’d):
				
		 		 		 	MPM ASSET MANAGEMENT INVESTORS 2004 BVIII LLC
					
		 		 		 	By:	 	/s/ Ansbert Gadicke
		 		 		 	Name:	 	Ansbert Gadicke
		 		 		 	Title:	 	General Partner
				
		 		 		 	TVM V LIFE SCIENCE VENTURES
				
		 		 		 	GMBH & CO. KG
					
		 		 		 	By:	 	/s/ Alexandra Goll
		 		 		 	Name:	 	Alexandra Goll
		 		 		 	Title:	 	Managing Limited Partner
					
		 		 		 	By:	 	/s/ Mark C. Cipriano
		 		 		 	Name:	 	Mark C. Cipriano
		 		 		 	Title:	 	 Managing Limited Partner

				
		 		 		 	TVM IV GMBH & CO. KG
					
		 		 		 	By:	 	/s/ Alexandra Goll
		 		 		 	Name:	 	Alexandra Goll
		 		 		 	Title:	 	Managing Limited Partner
					
		 		 		 	By:	 	/s/ John J. DiBello
		 		 		 	 Name:
	 	John J. DiBello
		 		 		 	 Title:
	 	Managing Limited Partner
				
		 		 		 	MDS LIFE SCIENCES TECHNOLOGY FUND II NC LIMITED PARTNERSHIP
				
		 		 		 	 By: MDS LSTF II (NCGP) Inc., its General Partner

					
		 		 		 	 By:
	 	/s/ Graysanne Bedell    /s/ Richard Lockie
		 		 		 	 Name:
	 	G. Bedell/ R. Lockie
		 		 		 	 Title:
	 	Vice President/ Vice President

  

 9 
 WAIVER AGREEMENT AND SECOND AMENDMENT TO THE 
 SECOND AMENDED AND RESTATED STOCKHOLDERS’ AGREEMENT 

									
		 		 		 	STOCKHOLDERS (Cont’d):
				
		 		 		 	MDS LIFE SCIENCES TECHNOLOGY FUND II QUEBEC LIMITED PARTNERSHIP
					
		 		 		 	By:	 	MDS LSTF II (QGP) Inc., its General Partner
					
		 		 		 	By:	 	/s/ Graysanne Bedell    /s/ Richard Lockie
		 		 		 	Name:	 	G. Bedell/ R. Lockie
		 		 		 	Title:	 	Vice President/ Vice President
				
		 		 		 	MLII CO-INVESTMENT FUND NC LIMITED PARTNERSHIP
					
		 		 		 	By:	 	MLII (NCGP) Inc., its General Partner
					
		 		 		 	By:	 	/s/ Graysanne Bedell    /s/ Richard Lockie
		 		 		 	Name:	 	G. Bedell/ R. Lockie
		 		 		 	Title:	 	Vice President/ Vice President
				
		 		 		 	CDIB BIOSCIENCE VENTURES I, INC.
					
		 		 		 	By:	 	/s/ Benny Hu
		 		 		 	Name:	 	Benny Hu
		 		 		 	Title:	 	Chairman

  

 10 
 WAIVER AGREEMENT AND SECOND AMENDMENT TO THE 
 SECOND AMENDED AND RESTATED STOCKHOLDERS’ AGREEMENT

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00103-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00103-of-00352.parquet"}]]